Vertex Pharmaceuticals Inc / Ma
2013 Q4 - 2025 Q4 (28 filings)
Shares History
History scope: non-option holdings only (PUT/CALL rows excluded).
| All 13F Holders | Filing date | Value ($000s) | % of Holdings | Shares | Reporting period |
|---|---|---|---|---|---|
| 2025 Q4 | 1/23/2026 | 296,711 | 0.2% | 654,470 | 12/31/2025 |
| 2025 Q3 | 10/27/2025 | 274,412 | 0.2% | 700,673 | 9/30/2025 |
| 2025 Q2 | 7/31/2025 | 291,628 | 0.2% | 655,050 | 6/30/2025 |
| 2025 Q1 | 4/25/2025 | 312,218 | 0.2% | 643,987 | 3/31/2025 |
| 2024 Q4 | 1/28/2025 | 265,594 | 0.2% | 659,533 | 12/31/2024 |
| 2024 Q3 | 11/5/2024 | 312,579 | 0.2% | 672,098 | 9/30/2024 |
| 2024 Q2 | 7/19/2024 | 311,878 | 0.2% | 665,382 | 6/30/2024 |
| 2024 Q1 | 4/19/2024 | 300,303 | 0.2% | 718,410 | 3/31/2024 |
| 2023 Q4 | 1/30/2024 | 289,143 | 0.2% | 710,616 | 12/31/2023 |
| 2023 Q3 | 10/30/2023 | 247,446 | 0.2% | 711,584 | 9/30/2023 |
| 2023 Q2 | 7/31/2023 | 254,093 | 0.2% | 722,041 | 6/30/2023 |
| 2023 Q1 | 4/27/2023 | 266,306 | 0.2% | 845,227 | 3/31/2023 |
| 2022 Q4 | 1/30/2023 | 246,880 | 0.2% | 854,908 | 12/31/2022 |
| 2022 Q3 | 10/21/2022 | 271,025 | 0.2% | 936,055 | 9/30/2022 |
| 2022 Q2 | 7/26/2022 | 261,588 | 0.2% | 928,307 | 6/30/2022 |
| 2022 Q1 | 4/27/2022 | 254,546 | 0.2% | 975,384 | 3/31/2022 |
| 2021 Q4 | 2/2/2022 | 228,328 | 0.1% | 1,039,746 | 12/31/2021 |
| 2021 Q3 | 10/25/2021 | 198,085 | 0.1% | 1,092,041 | 9/30/2021 |
| 2021 Q2 | 8/2/2021 | 225,595 | 0.1% | 1,118,858 | 6/30/2021 |
| 2021 Q1 | 4/30/2021 | 269,522 | 0.2% | 1,254,233 | 3/31/2021 |
| 2020 Q4 | 2/5/2021 | 304,378 | 0.2% | 1,287,882 | 12/31/2020 |
| 2020 Q3 | 10/30/2020 | 358,643 | 0.2% | 1,317,959 | 9/30/2020 |
| 2020 Q2 | 7/27/2020 | 387,407 | 0.3% | 1,334,460 | 6/30/2020 |
| 2020 Q1 | 4/27/2020 | 308,909 | 0.3% | 1,298,209 | 3/31/2020 |
| 2019 Q4 | 1/31/2020 | 271,957 | 0.2% | 1,242,096 | 12/31/2019 |
| 2014 Q2 | 8/11/2014 | 52,006 | 0.1% | 549,282 | 6/30/2014 |
| 2014 Q1 | 5/9/2014 | 40,669 | 0.1% | 575,068 | 3/31/2014 |
| 2013 Q4 | 2/14/2014 | 43,046 | 0.1% | 582,562 | 12/31/2013 |